Related Experiment Video

Updated: Oct 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Multifarious targets beyond microtubules-role of eribulin in cancer therapy

Priya Seshadri1, Barnali Deb1,2, Prashant Kumar1,2,3

  • 1Institute of Bioinformatics, International Technology Park, 560066 Bengaluru, Karnataka, India.

Frontiers in Bioscience (Scholar Edition)
|December 8, 2021
PubMed

Insights

Eribulin, a marine-derived anticancer drug, shows broad efficacy by targeting cancer cells and their microenvironment through multiple mechanisms. Future strategies aim to overcome resistance and toxicity for broader clinical use.

Area of Science:

  • Pharmacology
  • Oncology
  • Marine Biotechnology

Background:

  • Eribulin, a synthetic marine-derived drug, exhibits significant anticancer potential.
  • Its primary mechanism involves microtubule inhibition, but multiple molecular actions are reported.
  • Eribulin targets both cancer cells and the tumor microenvironment.

Purpose of the Study:

  • To review the diverse mechanisms of action of eribulin against cancer cells.
  • To present clinical aspects of eribulin in cancer management.
  • To explore strategies for enhancing eribulin efficacy, including combination therapy.

Main Methods:

  • Comprehensive literature review of preclinical and clinical data.
  • Analysis of eribulin's molecular targets and pathways.
  • Evaluation of current clinical applications and future therapeutic strategies.

Main Results:

  • Eribulin demonstrates anticancer activity through various molecular mechanisms.
  • Current applications include metastatic breast cancer and liposarcoma treatment.
  • Combination therapies and strategies to mitigate toxicity and resistance are under investigation.

Conclusions:

  • Eribulin is a valuable anticancer agent with diverse mechanisms of action.
  • Addressing toxicity and resistance is crucial for its wider clinical adoption.
  • Further research may position eribulin as a first-line cancer treatment.
Keywords:
Cancer therapyEribulinMicrotubule inhibitionReversal of EMTReview

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K